DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China
· Delayed Price · Currency is CNY 19.45
-0.37 (-1.87%)
At close: Mar 9, 2026
SHA:603233 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 22,151 | 17,151 | 28,359 | 37,585 | 33,307 | 51,603 | Upgrade
|
| Market Cap Growth | 37.55% | -39.52% | -24.55% | 12.85% | -35.46% | 89.92% | Upgrade
|
| Enterprise Value | 22,741 | 20,006 | 31,251 | 40,044 | 35,732 | 49,307 | Upgrade
|
| Last Close Price | 19.45 | 14.49 | 23.01 | 29.92 | 26.12 | 40.01 | Upgrade
|
| PE Ratio | 19.23 | 18.75 | 24.31 | 36.29 | 42.10 | 48.58 | Upgrade
|
| Forward PE | 17.23 | 16.44 | 23.76 | 31.37 | 28.06 | 49.98 | Upgrade
|
| PS Ratio | 0.83 | 0.65 | 1.16 | 1.77 | 1.99 | 3.54 | Upgrade
|
| PB Ratio | 2.61 | 2.11 | 3.58 | 5.48 | 5.61 | 9.26 | Upgrade
|
| P/TBV Ratio | 12.75 | 12.20 | 14.61 | 11.71 | 11.90 | 14.49 | Upgrade
|
| P/FCF Ratio | 5.65 | 10.52 | 20.59 | 13.81 | 128.08 | 44.42 | Upgrade
|
| P/OCF Ratio | 5.12 | 5.52 | 8.94 | 10.01 | 21.42 | 26.41 | Upgrade
|
| PEG Ratio | 1.01 | 0.45 | 0.88 | 1.05 | 1.44 | - | Upgrade
|
| EV/Sales Ratio | 0.85 | 0.76 | 1.27 | 1.89 | 2.13 | 3.38 | Upgrade
|
| EV/EBITDA Ratio | 6.43 | 6.39 | 9.63 | 22.15 | 27.36 | 32.16 | Upgrade
|
| EV/EBIT Ratio | 12.29 | 12.93 | 17.40 | 25.18 | 32.45 | 36.19 | Upgrade
|
| EV/FCF Ratio | 5.80 | 12.27 | 22.69 | 14.71 | 137.41 | 42.45 | Upgrade
|
| Debt / Equity Ratio | 0.70 | 0.95 | 0.82 | 0.86 | 0.89 | 0.25 | Upgrade
|
| Debt / EBITDA Ratio | 1.68 | 2.47 | 2.01 | 2.06 | 2.34 | 0.91 | Upgrade
|
| Debt / FCF Ratio | 1.52 | 4.75 | 4.73 | 2.18 | 20.29 | 1.21 | Upgrade
|
| Net Debt / Equity Ratio | -0.08 | 0.19 | 0.26 | 0.20 | 0.40 | -0.55 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.19 | 0.48 | 0.63 | 0.74 | 1.82 | -1.98 | Upgrade
|
| Net Debt / FCF Ratio | -0.17 | 0.92 | 1.49 | 0.50 | 9.13 | -2.62 | Upgrade
|
| Asset Turnover | 1.03 | 1.05 | 1.09 | 1.11 | 1.13 | 1.39 | Upgrade
|
| Inventory Turnover | 4.26 | 4.19 | 3.92 | 3.53 | 3.29 | 3.80 | Upgrade
|
| Quick Ratio | 0.62 | 0.58 | 0.54 | 0.62 | 0.55 | 0.93 | Upgrade
|
| Current Ratio | 0.96 | 0.92 | 0.94 | 1.10 | 1.10 | 1.52 | Upgrade
|
| Return on Equity (ROE) | 14.75% | 12.20% | 16.63% | 16.86% | 13.98% | 21.87% | Upgrade
|
| Return on Assets (ROA) | 4.45% | 3.83% | 4.99% | 5.21% | 4.64% | 8.11% | Upgrade
|
| Return on Invested Capital (ROIC) | 16.16% | 11.54% | 14.93% | 14.69% | 15.65% | 44.62% | Upgrade
|
| Return on Capital Employed (ROCE) | 14.50% | 12.20% | 14.20% | 14.30% | 10.80% | 19.90% | Upgrade
|
| Earnings Yield | 5.14% | 5.33% | 4.11% | 2.76% | 2.38% | 2.06% | Upgrade
|
| FCF Yield | 17.71% | 9.51% | 4.86% | 7.24% | 0.78% | 2.25% | Upgrade
|
| Dividend Yield | 3.43% | 4.28% | 1.35% | 1.67% | 1.33% | 1.16% | Upgrade
|
| Payout Ratio | 66.05% | 82.34% | 51.82% | 40.58% | 67.53% | 31.38% | Upgrade
|
| Buyback Yield / Dilution | 0.96% | 0.28% | 0.50% | -0.69% | 0.24% | -2.65% | Upgrade
|
| Total Shareholder Return | 4.39% | 4.56% | 1.84% | 0.98% | 1.57% | -1.49% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.